Good price  online

products details

Created with Pixso. Home Created with Pixso. Products Created with Pixso.
Urogenital Cancer Drugs
Created with Pixso. Olaparib Tablets 150mg 56 Tablets Box PARP Inhibitor for BRCA Mutated Ovarian Breast Pancreatic Prostate Cancer Therapy

Olaparib Tablets 150mg 56 Tablets Box PARP Inhibitor for BRCA Mutated Ovarian Breast Pancreatic Prostate Cancer Therapy

Brand Name: Sichuan Kelun Pharmaceutical Co., Ltd.
Model Number: Olaparib KL-20243062
MOQ: Negotiable
Price: Please contact a specialist WhatsApp:55342706
Delivery Time: Negotiable
Payment Terms: Western Union,MoneyGram,T/T
Detail Information
Place of Origin:
Chengdu, Sichuan, China
Certification:
NMPA/GMP
Packaging Details:
Negotiable
Supply Ability:
Negotiable
Highlight:

PARP Inhibitor Targeted Therapy

,

BRCA Mutated Ovarian Cancer Drug

,

Synthetic Lethality Cancer Treatment

Product Description

Olaparib 150mg x 56 Tablets

[Product Name]

Generic Name: Olaparib

Specification: 150mg x 56 Tablets

[Active Ingredient]

Olaparib

[Indications]

1. BRCA-mutated advanced ovarian cancer maintenance. 2. HER2- metastatic breast cancer with gBRCA. 3. gBRCA-mutated metastatic pancreatic cancer. 4. mCRPC with HRR mutations.

[Mechanism of Action]

PARP inhibitor trapping PARP on DNA, creating synthetic lethality in BRCA-mutated/HRD cancer cells deficient in homologous recombination repair.

[Dosage]

300mg (2 tablets) twice daily. Total 600mg/day. Swallow whole. With or without food.

[Adverse Reactions]

Nausea (77%), fatigue (67%), anemia (44%), vomiting, diarrhea. MDS/AML (rare but fatal), pneumonitis, VTE.

[Storage]

Store below 30C. Keep out of reach of children.

[Shelf Life]

24 months

Approval: H20243062